Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX
Lexicon Pharmaceuticals — Investor Presentation (December 2024)
17 slides from Lexicon Pharmaceuticals's investor presentation, December 2024
Slide 1: December 2024 Investor Presentation
December 2024 Investor Presentation ‹#›
Slide 2: Forward-Looking Statements
Forward-Looking Statements • This presentation, including any oral presentation accompanying it, contains “forward-looking statements,” including statements about Lexicon’s strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as pr
Slide 3: 2024 progress has fueled optionality for the future
Company Overview 2024 progress has fueled optionality for the future Refocused resources where Lexicon has potential to Lead to Succeed Accelerated top-line data readout of PROGRESS, Phase 2b dose optimization study of LX9211 in DPNP to Q1 2025 Ongoing enrollment in pivotal Phase 3 study of sotaglif
Slide 4: Repositioning Lexicon as a Clinical-Development Company
Company Overview Recent Strategic Restructuring Propels Development Focused Strategy Prioritizing resources on strong R&D pipeline including ongoing clinical studies in DPNP, HCM and IND-enabling studies in obesity Repositioning Lexicon as a Clinical- Restructuring to eliminate major commercial Deve
Slide 5: Pipeline assets position Lexicon for near-term and future growth
Pipeline Pipeline assets position Lexicon for near-term and future growth Preclinical Phase 1 Phase 2 Phase 3 Registration Approved INPEFA® (Sotagliflozin) Approved for Heart Failure Sotagliflozin Hypertrophic Cardiomyopathy Phase 3 registrational study commenced; multiple sites open (HCM) LX9211 Di
Slide 6: LX9211 has multiple possible therapeutic applications across neuropathic pain
LX9211 LX9211 has multiple possible therapeutic applications across neuropathic pain Potential Advantages of LX9211 Diabetic Peripheral Neuropathic Novel AAK1 mechanism Pain (DPNP) Oral once daily, non-opioid Promising pre-clinical LX9211 studies Spasticity Post Hepatic Neuralgia Potential first new
Slide 7: PROGRESS Phase 2b study enrollment complete
LX9211 PROGRESS Phase 2b study enrollment complete Topline data read-out now anticipated for Q1 2025 Aligns with how DPNP Patient Safety Follow- drugs are likely to be Treatment Period Population up used in practice LX9211 10 mg Placebo controlled study Adult patients LX9211 20 mg with a diagnosis R
Slide 8: LX9211 meaningfully reduced ADPS in a previous Phase 2 study
LX9211 LX9211 meaningfully reduced ADPS in a previous placebo-controlled Phase 2 study while patients remained on SOC Patients allowed to Historical Data LX9211.201 continue background Placebo Pregabalin Placebo LX9211 SOC 0 2-week run-in period LS Mean Change from Baseline -1 Δ = -0.67 Study design
Slide 9: Sotagliflozin has Potential to Occupy a Unique Position in Symptomatic HCM
Sotagliflozin HCM Sotagliflozin has Potential to Occupy a Unique Position in Symptomatic HCM HCM Disease Progression and Treatment Journey First Line Severe/Obstructive Hypertrophic Continued Disease Progression Cardiomyopathy Treatment Beta Blocker (BB) +/- Sotaglifozin Opportunity Cardiac Myosin S
Slide 10: SONATA Phase 3 study for oHCM and nHCM
Sotagliflozin HCM SONATA Phase 3 study for oHCM and nHCM Global Phase 3 SONATA Trial Sotagliflozin 400 mg* (N = 250) Enrollment underway R 1:1 Placebo (N = 250) Only ongoing trial to evaluate both obstructive Up to 14 days 4-week and non-obstructive HCM Double-blind treatment period screening Follow
Slide 11: Potential to address unmet needs in obesity & related cardiometabolic disorders
LX9851 Potential to address unmet needs in obesity & related cardiometabolic disorders GLP-1 Treatment Potential Advantages Biology-based Mechanism to Challenges of LX9851 Address Obesity • Muscle wasting • Oral agent / chronic use Induces satiety • Patient tolerability • Reduction in body fat • Inj
Slide 12: LX9851 helps maintain weight loss after semaglutide discontinuation in mice
LX9851 LX9851 helps maintain weight loss after semaglutide discontinuation in HFD-fed DIO mice 52 Semaglutide Withdrawal After Initial Weight Loss 50 48 46 * * ** Body Weight (g) 44 42 * 40 38 * 36 ** *** ** 34 Semaglutide treatment Control #1: PBS withdrawn after day 14 Semaglutide (0-14); w/o (15-
Slide 13: Partnering is an important element of our Lead to Succeed strategy
Partnering Partnering is an important element of our Lead to Succeed strategy Pursuing partnerships as a source of non-dilutive capital to maximize the value of our Augmenting Expanding portfolio Commercial Access to New Capabilities Geographies Significant opportunities for partnering remain ahead
Slide 14: Viatris license expands reach of sotagliflozin
Partnering Viatris license expands reach of sotagliflozin while preserving partnership opportunities for other assets, territories and indications $25M upfront payment provides non-dilutive capital to advance pipeline programs Exclusive licensing Nearly $200M potential in regulatory and sales milest
Slide 15: Significant Opportunities Exist in Expanded Deep Pipeline
Company Overview Significant Opportunities Exist in Expanded Deep Pipeline Target Preclinical Phase 1 Phase 2 Phase 3 Approved LX9211 Neuropathic Pain AAK1 Neuropathic Pain Diabetic Peripheral Neuropathic Pain AAK1 Post Hepatic Neuralgia AAK1 Chemotherapy Induced Neuropathic Pain AAK1 Painful Lumbos
Slide 16: Significant number of planned catalysts through 2025
Conclusions Significant number of planned catalysts through 2025 Pipeline Indication Planned Catalyst 2024 – 2025 • Phase 3 study commenced Sotagliflozin • Hypertrophic Cardiomyopathy • Enrollment underway • Enrollment completion 2024 LX9211 • Diabetic Peripheral Neuropathic Pain • Top line data Q1
Slide 17: Thank You
Thank You w Lexicon pharmaceuticals
Lexicon Pharmaceuticals — Investor Presentation (December 2024) on 6ix